CompletedPhase 1NCT00121849

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Access to Advanced Health Institute (AAHI)
Principal Investigator
Iván D Vélez Bernal, MD, PhD
PECET, Medellin, Colombia
Intervention
Leish-111f + MPL-SE vaccine(biological)
Enrollment
12 enrolled
Eligibility
18-40 years · All sexes
Timeline
2005 – 2006

Study locations (1)

Collaborators

Bill and Melinda Gates Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00121849 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis →

← Back to all trials